

IN THE CLAIMS:

Please amend claims 18-23 and 25 as follows. Following is a clean version of claims 18-23 and 25. A marked-up version of claims 18-23 and 25 are attached hereto on separate sheets.

sub C-1  
18. (Amended) A biologically active substance comprising a substance selected from the group consisting of the CHIPS protein and biologically active fragments thereof.

sub C-1  
19. (Amended) A medicine comprising a substance selected from the group consisting of the CHIPS protein having a biological activity which consists of the capacity to prevent the binding of fMLP and/or C5a to granulocytes in a test as described in example 1, under 1.2, and fragments thereof that have said biological activity and biologically active fragments thereof.

B1  
20. (Amended) A method of treatment of acute and chronic inflammation reactions and HIV infection comprising administration of a substance selected from the group consisting of the CHIPS protein having a biological activity which consists of the capacity to prevent the binding of fMLP and/or C5a to granulocytes in a test as described in example 1, under 1.2, and fragments thereof that have said biological activity and biologically active fragments thereof.

21. (Amended) Antibodies against a substance selected from the group consisting of the CHIPS protein having a biological activity which consists of the capacity to

C1  
B1  
prevent the binding of fMLP and/or C5a to granulocytes in a test as described in example 1, under 1.2, and fragments thereof that have said biological activity and biologically active fragments thereof.

22. (Amended) A method for the treatment of *Staphylococcus* infection comprising the administration of antibodies against a substance selected from the group consisting of the CHIPS protein having a biological activity which consists of the capacity to prevent the binding of fMLP and/or C5a to granulocytes in a test as described in example 1, under 1.2, and fragments thereof that have said biological activity and biologically active fragments thereof.

23. (Amended) A therapeutic composition comprising a suitable excipient and a substance selected from the group consisting of the CHIPS protein having a biological activity which consists of the capacity to prevent the binding of fMLP and/or C5a to granulocytes in a test as described in example 1, under 1.2, and fragments thereof that have said biological activity and biologically active fragments thereof.

C1  
B2  
25. (Amended) A therapeutic composition comprising a suitable excipient and one or more antibodies against a substance selected from the group consisting of the CHIPS protein having a biological activity which consists of the capacity to prevent the binding of fMLP and/or C5a to granulocytes in a test as described in example 1, under 1.2, and fragments thereof that have said biological activity and biologically active fragments thereof.